Prof. Shenshan Jia 贾深汕
Chief Physician, Professor
Department of Head and Neck Surgery (II), Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and surgical treatment of benign and malignant tumors of the larynx, thyroid, tongue, mouth floor, jaws, parotid, and submandibular glands. Performs post-operative defect reconstruction for head and neck cancers.
Dr. Jia graduated from Harbin Medical University in 1968 and trained at Washington University School of Medicine in 1991. A Professor and Chief Physician, Dr. Jia has over 30 years of experience in head and neck surgery, focusing on laryngeal function-preserving procedures and reconstructive techniques such as free jejunum transplantation and myocutaneous flaps.
Professional roles
- Member, Head and Neck Surgical Oncology Committee, China Anti-Cancer Association
- Vice Chair, Trauma Rehabilitation Committee, Chinese Association of Rehabilitation Medicine
- Standing Committee Member, Laryngectomee Rehabilitation Committee, China Disabled Persons' Federation Rehabilitation Association
- Vice Chair, Heilongjiang Provincial Otolaryngology Society
Name order: in Chinese the family name comes first (Jia Shenshan). Papers usually list the name as Shenshan Jia or Jia S.
Selected publications
4 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Cancer Res Clin Oncol, 2022 (first author): Efficacy of superselective neck dissection (IIA and III) for supraglottic laryngeal cancer with clinically negative neck. PubMed 34286400
- Pathol Oncol Res, 2021 (senior author): LncRNA LINC-PINT Inhibits Malignant Behaviors of Laryngeal Squamous Cell Carcinoma Cells via Inhibiting ZEB1. PubMed 34257531
- J Cell Mol Med, 2018 (senior author): Long non-coding RNA AFAP1-AS1/miR-320a/RBPJ axis regulates laryngeal carcinoma cell stemness and chemoresistance. PubMed 29971915
- Biomed Pharmacother, 2016 (senior author): Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-κB/mTOR and ERK1/2 signaling pathways. PubMed 27551764
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion